DK0689449T3 - Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin - Google Patents

Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin

Info

Publication number: DK0689449T3
Authority: DK; Denmark
Prior art keywords: pct; cytokine; muramyl peptide; preparations; combining
Prior art date: 1993-03-19

Application number

DK94910445T

Other languages

Danish (da)

English (en)

Inventor

Louis Chedid

Georges Bahr

Pierre Lefrancier

Original Assignee

Vacsyn Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-19

Filing date

1994-03-21

Publication date

2003-03-03

1993-03-19 Priority claimed from FR9303230A external-priority patent/FR2702659B1/fr

1993-03-31 Priority claimed from FR9303787A external-priority patent/FR2703251B3/fr

1994-03-21 Application filed by Vacsyn Sa filed Critical Vacsyn Sa

2003-03-03 Application granted granted Critical

2003-03-03 Publication of DK0689449T3 publication Critical patent/DK0689449T3/da

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Virology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK94910445T 1993-03-19 1994-03-21 Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin DK0689449T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR9303230A FR2702659B1 (fr)	1993-03-19	1993-03-19	Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine.
FR9303787A FR2703251B3 (fr)	1993-03-31	1993-03-31	Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine .
PCT/FR1994/000307 WO1994021275A1 (fr)	1993-03-19	1994-03-21	Compositions pour l'application en therapeutique humaine, caracterisees par l'association d'un muramyl-peptide a une cytokine

Publications (1)

Publication Number	Publication Date
DK0689449T3 true DK0689449T3 (da)	2003-03-03

Family

ID=26230187

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94910445T DK0689449T3 (da)	1993-03-19	1994-03-21	Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin

Country Status (11)

Country	Link
US (1)	US5932208A (pt)
EP (1)	EP0689449B1 (pt)
JP (1)	JP3723206B2 (pt)
AT (1)	ATE226828T1 (pt)
AU (1)	AU6285694A (pt)
CA (1)	CA2157758A1 (pt)
DE (1)	DE69431620T2 (pt)
DK (1)	DK0689449T3 (pt)
ES (1)	ES2187520T3 (pt)
PT (1)	PT689449E (pt)
WO (1)	WO1994021275A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6858409B1 (en)	1988-05-27	2005-02-22	Amgen Inc.	Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US6159460A (en) *	1988-05-27	2000-12-12	Amgen Inc.	Method for treating interleukin-1 mediated diseases
US5075222A (en)	1988-05-27	1991-12-24	Synergen, Inc.	Interleukin-1 inhibitors
US6267968B1 (en) *	1995-04-07	2001-07-31	Vacsyn S.A.	MDP derivatives and conjugates having haematipoietic function stimulating activity, and compositions containing same
JP4771563B2 (ja)	1996-12-06	2011-09-14	アムジエン・インコーポレーテツド	Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US6294170B1 (en)	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
US6013253A (en) *	1997-08-15	2000-01-11	Amgen, Inc.	Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US8106098B2 (en)	1999-08-09	2012-01-31	The General Hospital Corporation	Protein conjugates with a water-soluble biocompatible, biodegradable polymer
CZ304942B6 (cs)	2000-03-31	2015-02-04	Purdue Research Foundation	Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl
FR2809106A1 (fr) *	2000-05-17	2001-11-23	Istac	Polypeptide ro/ssa-like et ses fragments et polynucleotides codant lesdits polypeptides et applications therapeutiques
ATE464068T1 (de)	2001-06-26	2010-04-15	Amgen Fremont Inc	Antikörper gegen opgl
AU2002316384A1 (en) *	2001-06-26	2003-03-03	Photomed Technologies, Inc.	Multiple wavelength illuminator
CA2461877A1 (en) *	2001-09-28	2003-04-10	Purdue Research Foundation	Method of treatment using ligand-immunogen conjugates
US20030097409A1 (en) *	2001-10-05	2003-05-22	Hungchou Tsai	Systems and methods for securing computers
EA033750B1 (ru)	2002-09-06	2019-11-21	Amgen Inc	Изолированная молекула нуклеиновой кислоты, кодирующая антитело человека к рецептору интерлейкина-1, и ее применение
EP1578782A4 (en) *	2002-12-30	2007-09-12	Amgen Inc	COSTIMULATING FACTORIAL THERAPY
US7546638B2 (en) *	2003-03-18	2009-06-09	Symantec Corporation	Automated identification and clean-up of malicious computer code
EP3138566B1 (en) *	2003-11-17	2022-01-26	BioMarin Pharmaceutical Inc.	Treatment of phenylketonuria with bh4
WO2006055511A2 (en) *	2004-11-17	2006-05-26	Biomarin Pharmaceutical Inc.	Stable tablet formulation of tetrahydrobiopterin
PE20070684A1 (es)	2005-11-14	2007-08-06	Amgen Inc	MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
WO2007092299A2 (en) *	2006-02-03	2007-08-16	Purdue Research Foundation	Targeted conjugates and radiation
US7767206B2 (en)	2006-10-02	2010-08-03	Amgen Inc.	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CN101918018B (zh)	2007-11-14	2012-12-05	再生医药有限公司	使用白介素-1受体拮抗剂作为骨髓保护剂的方法
TW201117824A (en)	2009-10-12	2011-06-01	Amgen Inc	Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh)	2009-10-26	2012-08-01	上海交通大学	白细胞介素-1受体拮抗剂的用途及其药物组合物
WO2013016220A1 (en)	2011-07-22	2013-01-31	Amgen Inc.	Il-17 receptor a is required for il-17c biology
US9216178B2 (en)	2011-11-02	2015-12-22	Biomarin Pharmaceutical Inc.	Dry blend formulation of tetrahydrobiopterin
US20160000936A1 (en)	2014-06-10	2016-01-07	Abbvie Inc.	Biomarkers for inflammatory disease and methods of using same
US10041044B2 (en)	2016-07-29	2018-08-07	Trustees Of Boston University	Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3836954A1 (en)	2018-08-13	2021-06-23	Iltoo Pharma	Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en)	2022-05-16	2023-11-23	Institut National de la Santé et de la Recherche Médicale	Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK585886A (da) *	1985-12-24	1987-06-25	Takeda Chemical Industries Ltd	Immunstimulerende middel og anvendelse deraf
IL83350A0 (en) *	1986-08-13	1987-12-31	Takeda Chemical Industries Ltd	Pharmaceutical compositions comprising interleukin and intterferon active substances
GB8803365D0 (en) *	1988-02-13	1988-03-16	Ciba Geigy Ag	Antiviral combination

1994
- 1994-03-21 DK DK94910445T patent/DK0689449T3/da active
- 1994-03-21 JP JP52072694A patent/JP3723206B2/ja not_active Expired - Fee Related
- 1994-03-21 DE DE69431620T patent/DE69431620T2/de not_active Expired - Fee Related
- 1994-03-21 US US08/522,342 patent/US5932208A/en not_active Expired - Fee Related
- 1994-03-21 EP EP94910445A patent/EP0689449B1/fr not_active Expired - Lifetime
- 1994-03-21 CA CA002157758A patent/CA2157758A1/en not_active Abandoned
- 1994-03-21 AU AU62856/94A patent/AU6285694A/en not_active Abandoned
- 1994-03-21 PT PT94910445T patent/PT689449E/pt unknown
- 1994-03-21 AT AT94910445T patent/ATE226828T1/de not_active IP Right Cessation
- 1994-03-21 WO PCT/FR1994/000307 patent/WO1994021275A1/fr active IP Right Grant
- 1994-03-21 ES ES94910445T patent/ES2187520T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ES2187520T3 (es)	2003-06-16
PT689449E (pt)	2003-03-31
DE69431620T2 (de)	2003-07-03
US5932208A (en)	1999-08-03
WO1994021275A1 (fr)	1994-09-29
ATE226828T1 (de)	2002-11-15
JPH08511235A (ja)	1996-11-26
EP0689449A1 (fr)	1996-01-03
DE69431620D1 (de)	2002-12-05
AU6285694A (en)	1994-10-11
JP3723206B2 (ja)	2005-12-07
EP0689449B1 (fr)	2002-10-30
CA2157758A1 (en)	1994-09-29

Publication	Publication Date	Title
DK0689449T3 (da)	2003-03-03	Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin
CA1288694C (en)	1991-09-10	Process for treatment of diseases
O'Suilleabhain et al.	1996	Interleukin-12 treatment restores normal resistance to bacterial challenge after burn injury
IT1261949B (it)	1996-06-04	Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
DK200500682A (da)	2005-05-11	Et rekombinant oplöseligt fragment af -subenhedpolypeptidet af human mastcelle IgE overfladereceptor samt anvendelse af samme
DK0708772T3 (da)	2000-09-18	Imidazo[4,5,-c]pyridin-4-aminer
KR950700333A (ko)	1995-01-16	개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
HUP0301003A2 (hu)	2003-07-28	Kazeinből származó peptidek és terápiás alkalmazásuk
DK0502036T3 (da)	1996-05-06	Latens-associeret peptid og anvendelser herfor
ATE402957T1 (de)	2008-08-15	Analoge des menschlichen interferon-alpha mit niedriger toxizität
EP0787802A3 (pt)	1997-08-27
DK0914144T3 (da)	2001-04-09	Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
DE59507920D1 (de)	2000-04-06	NEUE hIL-4-MUTANTENPROTEINE ALS ANTAGONISTEN ODER PARTIELLE AGONISTEN DES HUMANEN INTERLEUKIN 4
DK0669979T3 (da)	2006-03-06	C-C CKR-1, kemokinreceptor
BRPI0317064B8 (pt)	2021-05-25	composições compreendendo células dendríticas parcialmente amadurecidas in vitro
DE69719754D1 (de)	2003-04-17	Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
NZ516477A (en)	2004-02-27	Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
DK0613499T3 (da)	1998-09-23	Humame IT-4-mutantproteiner
NO964200L (no)	1996-10-03	Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller Th2-forsterkende cytokiner
SE9201966D0 (sv)	1992-06-25	Interleukin-1beta deletion mutant
HUP0000248A2 (hu)	2000-06-28	Nagy affinitású interleukin-4 muteinek
CA2388338A1 (en)	2001-05-03	Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
ATE159172T1 (de)	1997-11-15	Peptide und deren verwendung
BR9713096A (pt)	2000-10-24	Lactação bovina associada à proteìna imunotrópica (cd14), gene codificado e aplicação na ativação de célula b
HK1015708A1 (en)	1999-10-22	Use of muteins of wild-type cytokines as immunogens.